Form 4: Xeris Biopharma Executive Beth Hecht Reports Stock Transactions

Xeris Biopharma's Chief Legal Officer, Beth Hecht, reports the acquisition and disposal of company stock and stock appreciation rights.

Summary

• Beth Hecht, Chief Legal Officer of Xeris Biopharma Holdings, Inc., filed a Form 4 detailing changes in her beneficial ownership of the company's stock.
• On January 31, 2025, Hecht disposed of 45,909 shares and 98,375 shares of common stock to cover income tax obligations related to vested restricted stock units, both at a price of $3.56 per share.
• She also acquired 185,000 shares of common stock through a restricted stock unit grant, with these shares vesting annually over three years.
• Additionally, Hecht was granted 300,000 stock appreciation rights, which will vest in full on the second anniversary of the grant date, and will be settled in cash upon exercise.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices and insider transactions, which are neither overly positive nor negative. The grant of equity is a positive sign of alignment with company goals.

Positives

• The grant of 185,000 restricted stock units and 300,000 stock appreciation rights indicates continued alignment of executive interests with the company's long-term performance.

Negatives

• The disposal of 144,284 shares to cover tax obligations may be seen as a slight reduction in the executive's direct shareholding.

Risks

• The vesting of the stock appreciation rights is contingent on continued service with the company, which could be a risk if there are changes in employment.

Future Outlook

The restricted stock units will vest in equal annual installments over three years, and the stock appreciation rights will vest in full on the second anniversary of the grant date, subject to continued service.

Management Comments

• Beth Hecht, Chief Legal Officer and Corporate Secretary, signed the Form 4.

Industry Context

This filing is a routine disclosure of insider transactions, which is common for publicly traded companies. It provides transparency into the stock ownership of key executives.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider transactions.
• The vesting schedules for restricted stock units and stock appreciation rights are typical for executive compensation packages in the biotech industry.
• The tax withholding of shares is a common practice to cover tax obligations related to equity compensation.

Stakeholder Impact

• Shareholders can monitor insider transactions for insights into management's view of the company's prospects.
• Employees may be interested in the details of executive compensation packages.

Next Steps

• The restricted stock units will continue to vest annually over the next three years.
• The stock appreciation rights will vest on the second anniversary of the grant date, subject to continued service.

Key Dates

Keywords

Xeris Biopharma, stock transactions, Form 4, insider trading, restricted stock units, stock appreciation rights, executive compensation, beneficial ownership